| Pulmonary Embolism
Xarelto vs Savaysa
Side-by-side clinical, coverage, and cost comparison for pulmonary embolism.Deep comparison between: Xarelto vs Savaysa with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSavaysa has a higher rate of injection site reactions vs Xarelto based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Savaysa but not Xarelto, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Xarelto
Savaysa
At A Glance
Oral
Once or twice daily
Factor Xa inhibitor
Oral
Daily
Factor Xa inhibitor
Indications
- Atrial Fibrillation
- Deep Vein Thrombosis
- Pulmonary Embolism
- Venous Thrombosis
- Coronary heart disease
- Peripheral Arterial Diseases
- Nonvalvular atrial fibrillation
- Deep Vein Thrombosis
- Pulmonary Embolism
Dosing
Atrial Fibrillation 20 mg once daily with evening meal (CrCl >50 mL/min); 15 mg once daily with evening meal (CrCl <=50 mL/min), oral.
Deep Vein Thrombosis, Pulmonary Embolism 15 mg twice daily with food for 21 days, then 20 mg once daily with food for remaining treatment, oral.
Venous Thrombosis 10 mg once daily with or without food: for recurrence prevention after at least 6 months of standard anticoagulant treatment; or 35 days post-hip replacement surgery; or 12 days post-knee replacement surgery; or 31-39 days total for prophylaxis in acutely ill medical patients, oral.
Coronary heart disease, Peripheral Arterial Diseases 2.5 mg twice daily with or without food, in combination with aspirin 75-100 mg once daily, oral.
Nonvalvular atrial fibrillation 60 mg orally once daily in patients with CrCL >50 to <=95 mL/min; reduce to 30 mg once daily for CrCL 15-50 mL/min; do not use in patients with CrCL >95 mL/min.
Deep Vein Thrombosis, Pulmonary Embolism 60 mg orally once daily following 5-10 days of initial parenteral anticoagulant therapy; reduce to 30 mg once daily for CrCL 15-50 mL/min, body weight <=60 kg, or concomitant use of certain P-gp inhibitors.
Contraindications
- Active pathological bleeding
- Severe hypersensitivity reaction to rivaroxaban or any excipient (e.g., anaphylactic reactions)
- Active pathological bleeding
Adverse Reactions
Most common Bleeding complications, wound secretion, pruritus, back pain, abdominal pain, muscle spasm, dizziness, fatigue
Serious Intracranial hemorrhage, gastrointestinal bleeding, fatal bleeding, spinal/epidural hematoma
Postmarketing Agranulocytosis, thrombocytopenia, jaundice, cholestasis, hepatitis, hypersensitivity, anaphylactic reaction, anaphylactic shock, angioedema, hemiparesis, anticoagulant-related nephropathy, eosinophilic pneumonia, Stevens-Johnson syndrome, DRESS, atraumatic splenic rupture
Most common (>=1%) Rash, abnormal liver function tests, anemia
Serious Intracranial hemorrhage, gastrointestinal bleeding, fatal bleeding
Postmarketing Thrombocytopenia, abdominal pain, angioedema, hypersensitivity, dizziness, headache, anticoagulant-related nephropathy, urticaria
Pharmacology
Rivaroxaban is a selective oral Factor Xa (FXa) inhibitor that does not require a cofactor for activity; by inhibiting free FXa and prothrombinase activity, it decreases thrombin generation and indirectly inhibits thrombin-induced platelet aggregation.
Edoxaban is a selective inhibitor of factor Xa (FXa) that does not require antithrombin III for antithrombotic activity; inhibition of FXa in the coagulation cascade reduces thrombin generation and thrombus formation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Xarelto
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (12/12)
Savaysa
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (4/12) · Qty limit (9/12)
UnitedHealthcare
Xarelto
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Savaysa
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (4/8)
Humana
Xarelto
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Savaysa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$10/fillfill
Xarelto withMe Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Savaysa.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
XareltoView full Xarelto profile
SavaysaView full Savaysa profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.